Over 20 Phase 2 and Phase 3 clinical trials were used in training this model, spanning 12 distinct therapeutic agents, including THF inhibitors, chemotaxis inhibitors, JAK inhibitors, and IL-23 inhibitor as well as combination thereof for both induction and maintenance phase of clinical trials.